Mechanisms of action of atypical antipsychotic drugs: A critical analysis

被引:278
作者
Kinon, BJ
Lieberman, JA
机构
[1] Department of Psychiatry, Hillside Hospital, Albert Einstein College of Medicine, Glen Oaks, NY 11004
关键词
review; atypical antipsychotic drug; schizophrenia; clozapine; haloperidol; catalepsy; extrapyramidal symptoms; tardive dyskinesia; dopamine receptor; biogenic amines; HALOPERIDOL-INDUCED CATALEPSY; MIDBRAIN DOPAMINE NEURONS; METHYL-D-ASPARTATE; C-FOS EXPRESSION; NEUROLEPTIC-INDUCED CATALEPSY; CHRONIC CLOZAPINE TREATMENT; MEDIAL PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS-SEPTI; MESSENGER-RNA LEVELS; FREELY MOVING RATS;
D O I
10.1007/BF02245602
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Various criteria used to define atypical antipsychotic drugs include: 1) decrease, or absence, of the capacity to cause acute extrapyramidal motor side effects (acute EPSE) and tardive dyskinesia (TD); 2) increased therapeutic efficacy reflected by improvement in positive, negative, or cognitive symptoms; 3) and a decrease, or absence. of the capacity to increase prolactin levels. The pharmacologic basis of atypical antipsychotic drug activity has been the target of intensive study since the significance of clozapine was first appreciated. Three notions have been utilized conceptually to explain the distinction between atypical versus typical antipsychotic drugs: 1) dose-response separation between particular pharmacologic functions; 2) anatomic specificity of particular pharmacologic activities; 3) neurotransmitter receptor interactions and pharmacodynamics. These conceptual bases are not mutually exclusive, and the demonstration of limbic versus extrapyramidal motor functional selectivity is apparent within each arbitrary theoretical base. This review discusses salient distinctions predominantly between prototypic atypical and typical antipsychotic drugs such as clozapine and haloperidol, respectively. In addition, areas of common function between atypical and typical antipsychotic drug action may also be crucial to our identification of pathophysiological foci of the different dimensions of schizophrenia, including positive symptoms, negative symptoms, and neurocognitive deficits.
引用
收藏
页码:2 / 34
页数:33
相关论文
共 515 条
[1]  
ACKENHEIL M, 1974, J PHARMACOL-PARIS, V5, P1
[2]  
ACKENHEIL M, 1977, PSYCHOTHERAPEUTIC 2, P923
[3]   BEHAVIORAL PROFILE OF RACLOPRIDE IN AGONISTIC ENCOUNTERS BETWEEN MALE-MICE [J].
AGUILAR, MA ;
MINARRO, J ;
PEREZIRANZO, N ;
SIMON, VM .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 47 (03) :753-756
[4]   REMOXIPRIDE AND HALOPERIDOL IN SCHIZOPHRENIA - A DOUBLE-BLIND MULTICENTER STUDY [J].
AHLFORS, UG ;
RIMON, R ;
APPELBERG, B ;
HAGERT, U ;
HARMA, P ;
KATILA, H ;
MAHLANEN, A ;
MEHTONEN, OP ;
NAUKKARINEN, H ;
OUTAKOSKI, J ;
RANTANEN, H ;
SORRI, A ;
TAMMINEN, T ;
TOLVANEN, E ;
HOLM, AC .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :99-103
[5]   EFFECTS OF TERGURIDE, A PARTIAL D2 AGONIST, ON MPTP-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS [J].
AKAI, T ;
YAMAGUCHI, M ;
MIZUTA, E ;
KUNO, S .
ANNALS OF NEUROLOGY, 1993, 33 (05) :507-511
[6]  
ALEKHINA TA, 1995, ZH VYSSH NERV DEYAT+, V45, P180
[7]  
ALTAR CA, 1988, N-S ARCH PHARMACOL, V338, P162
[8]   EFFECT OF CLOZAPINE ON TURNOVER OF DOPAMINE IN CORPUS STRIATUM AND IN LIMBIC SYSTEM [J].
ANDEN, N ;
STOCK, G .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (04) :346-348
[9]   A DOUBLE-BLIND COMPARATIVE MULTICENTER STUDY OF REMOXIPRIDE AND HALOPERIDOL IN SCHIZOPHRENIA [J].
ANDERSEN, J ;
KORNER, A ;
OSTERGAARD, P ;
FENSBO, C ;
BIRKETSMITH, M ;
THIESEN, S ;
HANSEN, NR ;
FOGH, M ;
KRISTENSEN, M ;
MOLLERNIELSEN, EM ;
JENSEN, B ;
BJORUM, N .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :104-107
[10]   CLOZAPINE AND HALOPERIDOL IN THE AMYGDALOID COMPLEX - DIFFERENTIAL-EFFECTS ON DOPAMINE TRANSMISSION WITH LONG-TERM TREATMENT [J].
ANDERSON, GD ;
REBEC, GV .
BIOLOGICAL PSYCHIATRY, 1988, 23 (05) :497-506